ETF Movers on Wednesday: TAN and NUGO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Source: NASDAQ.COM
ETF Performance: The Nuveen Growth Opportunities ETF is underperforming, down approximately 2.1% in Wednesday afternoon trading.
Weakest Components: Key contributors to the ETF's decline include Arista Networks, which fell by about 6.9%, and Dexcom, which decreased by about 3.3%.
Market Context: The article highlights the performance of specific ETFs and their components, indicating broader market trends.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DXCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise
16 Analyst Rating
13 Buy
2 Hold
1 Sell
Strong Buy
Current: 68.860
Low
68.00
Averages
82.54
High
100.00
Current: 68.860
Low
68.00
Averages
82.54
High
100.00
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into DexCom Shareholder Rights
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of DexCom, Inc. breached their fiduciary duties, potentially exposing shareholders to risks of diminished rights.
- Legal Fee Structure: The firm operates on a contingent fee basis, ensuring that shareholders pursuing legal remedies do not incur upfront costs, thereby lowering the barrier for shareholder participation.
- Opportunity for Governance Reform: Long-term DexCom shareholders may seek corporate governance reforms, fund recovery, or court-approved financial incentives, aimed at enhancing transparency and accountability, which could ultimately increase shareholder value.
- Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms; Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented reforms that recovered millions for defrauded investors.
See More
Two Stocks Wall Street Loves and One to Sell
- Sell Recommendation for LKQ: LKQ's consensus price target is $40.81, implying a 55.8% return; however, its organic sales performance suggests a need for strategic adjustments or M&A to catalyze growth, while declining returns on capital indicate that recent investments are destroying value.
- Positive Outlook for DexCom: DexCom's consensus price target is $84.67, with a 22.5% implied return, as its organic revenue growth averaged 12.5% over the past two years, and its free cash flow margin has increased by 26 percentage points, showcasing strong market opportunities.
- Strong Fundamentals for Pfizer: Pfizer's consensus price target is $29.19, indicating a 22.2% implied return, supported by a massive revenue base of $63.32 billion in a highly regulated sector, enhancing its negotiating power, while adjusted operating profits have increased over the past two years.
- Market Outlook Analysis: While LKQ faces challenges, the strong fundamentals of DexCom and Pfizer support Wall Street's optimistic outlook, prompting investors to consider the long-term growth potential of these companies.
See More
Deutsche Bank Initiates Buy Ratings for Insulet and DexCom Amid Market Recovery
- Market Recovery Signal: Deutsche Bank has initiated Buy ratings for insulin pump manufacturers Insulet (PODD) and DexCom (DXCM), despite both companies shedding over 40% of their market value in the past three years, indicating a renewed assessment of investment opportunities in the diabetes care sector.
- Price Target Setting: Deutsche Bank has set price targets of $190 for Insulet and $86 for DexCom, reflecting analysts' confidence in the future growth potential of these companies, while Tandem Diabetes (TNDM) received a Hold rating with a target price of $15.50.
- Investment Attractiveness: Analyst Kieran Ryan highlighted PODD as an ideal entry point for medium-term investors, offering one of the strongest growth algorithms among mid- to large-cap medtech firms at a time when attractive growth stories are scarce.
- Signs of DexCom Recovery: Ryan noted that DexCom could be
See More
Dexcom Launches Pediatric Stelo and New App Experience
- Regulatory Milestone: At Aspen Ideas: Health, Dexcom announced pediatric clearance for the Stelo glucose biosensor, significantly enhancing accessibility for glucose monitoring in children, which is expected to improve diabetes management for younger patients.
- App Revamp: The company plans to launch a fully reimagined Stelo app experience in July for U.S. users, aimed at making glucose insights more approachable and actionable, thereby empowering users to manage their health more effectively.
- International Expansion: Dexcom also announced plans to expand Stelo's availability to the UK, Australia, New Zealand, and South Korea later this year, with further international rollout expected by 2027, enhancing its global market presence.
- Industry Leadership: As the global leader in glucose biosensing, these initiatives not only solidify Dexcom's market position but also lay the groundwork for future growth, addressing the increasing demand for effective health management solutions.
See More
Major Rating Changes on Wall Street
- IBM Upgrade: JPMorgan upgraded IBM from Neutral to Overweight, citing a deeper analysis of its software business that suggests significant performance acceleration in 2H'26, thereby enhancing market confidence in the company's growth trajectory.
- Qiagen Upgrade: Morgan Stanley upgraded Qiagen from Equal Weight to Overweight, noting that AI-driven growth improvements and the clearing of competitive risks are expected to positively impact the life sciences sector.
- Smurfit Westrock Initiation: Deutsche Bank initiated coverage of Smurfit Westrock with a Buy rating and a $57 price target, emphasizing its high-margin operations and strong market position as catalysts for value creation in the packaging industry.
- Target Upgrade: Wolfe upgraded Target from Peer Perform to Outperform, stating that now is the optimal time to buy, as the company is poised for significant improvements driven by store resets and a new leadership team shaking up the status quo.
See More
Abbott's Q2 Earnings Preview and Growth Drivers
- Diversified Business Model: Abbott operates across four major segments—medical devices, diagnostics, nutrition, and established pharmaceuticals—reporting $5.5 billion in medical device revenue in Q1 2023, which constitutes about 50% of total sales, showcasing resilience in changing healthcare and economic environments.
- Diabetes Care Growth: The FreeStyle Libre continuous glucose monitoring platform generated approximately $2 billion in Q1 sales with over 7 million users globally, and with diabetes prevalence expected to exceed 850 million by 2050, Abbott has significant growth potential in this area.
- Cardiovascular Business Boost: Abbott's cardiovascular segment achieved around $578 million in Q1 revenue, with products like MitraClip and TriClip capturing an increasing share of the minimally invasive heart repair market, which is projected to expand significantly over the next decade.
- Steady Revenue Streams: Abbott's diagnostics and nutrition segments produced approximately $2.1 billion and $2 billion in Q1 sales, respectively, with brands like Ensure and Glucerna providing recurring revenue that helps offset fluctuations in other business areas.
See More
Investigation into DexCom Shareholder Rights
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of DexCom, Inc. breached their fiduciary duties, potentially exposing shareholders to risks of diminished rights.
- Legal Fee Structure: The firm operates on a contingent fee basis, ensuring that shareholders pursuing legal remedies do not incur upfront costs, thereby lowering the barrier for shareholder participation.
- Opportunity for Governance Reform: Long-term DexCom shareholders may seek corporate governance reforms, fund recovery, or court-approved financial incentives, aimed at enhancing transparency and accountability, which could ultimately increase shareholder value.
- Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms; Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented reforms that recovered millions for defrauded investors.
See More
Two Stocks Wall Street Loves and One to Sell
- Sell Recommendation for LKQ: LKQ's consensus price target is $40.81, implying a 55.8% return; however, its organic sales performance suggests a need for strategic adjustments or M&A to catalyze growth, while declining returns on capital indicate that recent investments are destroying value.
- Positive Outlook for DexCom: DexCom's consensus price target is $84.67, with a 22.5% implied return, as its organic revenue growth averaged 12.5% over the past two years, and its free cash flow margin has increased by 26 percentage points, showcasing strong market opportunities.
- Strong Fundamentals for Pfizer: Pfizer's consensus price target is $29.19, indicating a 22.2% implied return, supported by a massive revenue base of $63.32 billion in a highly regulated sector, enhancing its negotiating power, while adjusted operating profits have increased over the past two years.
- Market Outlook Analysis: While LKQ faces challenges, the strong fundamentals of DexCom and Pfizer support Wall Street's optimistic outlook, prompting investors to consider the long-term growth potential of these companies.
See More
Deutsche Bank Initiates Buy Ratings for Insulet and DexCom Amid Market Recovery
- Market Recovery Signal: Deutsche Bank has initiated Buy ratings for insulin pump manufacturers Insulet (PODD) and DexCom (DXCM), despite both companies shedding over 40% of their market value in the past three years, indicating a renewed assessment of investment opportunities in the diabetes care sector.
- Price Target Setting: Deutsche Bank has set price targets of $190 for Insulet and $86 for DexCom, reflecting analysts' confidence in the future growth potential of these companies, while Tandem Diabetes (TNDM) received a Hold rating with a target price of $15.50.
- Investment Attractiveness: Analyst Kieran Ryan highlighted PODD as an ideal entry point for medium-term investors, offering one of the strongest growth algorithms among mid- to large-cap medtech firms at a time when attractive growth stories are scarce.
- Signs of DexCom Recovery: Ryan noted that DexCom could be
See More
Dexcom Launches Pediatric Stelo and New App Experience
- Regulatory Milestone: At Aspen Ideas: Health, Dexcom announced pediatric clearance for the Stelo glucose biosensor, significantly enhancing accessibility for glucose monitoring in children, which is expected to improve diabetes management for younger patients.
- App Revamp: The company plans to launch a fully reimagined Stelo app experience in July for U.S. users, aimed at making glucose insights more approachable and actionable, thereby empowering users to manage their health more effectively.
- International Expansion: Dexcom also announced plans to expand Stelo's availability to the UK, Australia, New Zealand, and South Korea later this year, with further international rollout expected by 2027, enhancing its global market presence.
- Industry Leadership: As the global leader in glucose biosensing, these initiatives not only solidify Dexcom's market position but also lay the groundwork for future growth, addressing the increasing demand for effective health management solutions.
See More
Major Rating Changes on Wall Street
- IBM Upgrade: JPMorgan upgraded IBM from Neutral to Overweight, citing a deeper analysis of its software business that suggests significant performance acceleration in 2H'26, thereby enhancing market confidence in the company's growth trajectory.
- Qiagen Upgrade: Morgan Stanley upgraded Qiagen from Equal Weight to Overweight, noting that AI-driven growth improvements and the clearing of competitive risks are expected to positively impact the life sciences sector.
- Smurfit Westrock Initiation: Deutsche Bank initiated coverage of Smurfit Westrock with a Buy rating and a $57 price target, emphasizing its high-margin operations and strong market position as catalysts for value creation in the packaging industry.
- Target Upgrade: Wolfe upgraded Target from Peer Perform to Outperform, stating that now is the optimal time to buy, as the company is poised for significant improvements driven by store resets and a new leadership team shaking up the status quo.
See More
Abbott's Q2 Earnings Preview and Growth Drivers
- Diversified Business Model: Abbott operates across four major segments—medical devices, diagnostics, nutrition, and established pharmaceuticals—reporting $5.5 billion in medical device revenue in Q1 2023, which constitutes about 50% of total sales, showcasing resilience in changing healthcare and economic environments.
- Diabetes Care Growth: The FreeStyle Libre continuous glucose monitoring platform generated approximately $2 billion in Q1 sales with over 7 million users globally, and with diabetes prevalence expected to exceed 850 million by 2050, Abbott has significant growth potential in this area.
- Cardiovascular Business Boost: Abbott's cardiovascular segment achieved around $578 million in Q1 revenue, with products like MitraClip and TriClip capturing an increasing share of the minimally invasive heart repair market, which is projected to expand significantly over the next decade.
- Steady Revenue Streams: Abbott's diagnostics and nutrition segments produced approximately $2.1 billion and $2 billion in Q1 sales, respectively, with brands like Ensure and Glucerna providing recurring revenue that helps offset fluctuations in other business areas.
See More
